Song Jaegyok, Choi Nayoung, Kang Minji, Ji Sung Mi, Kim Dong-Wook, Kwon Min A
Department of Anesthesiology and Pain Medicine, Dankook University Hospital, Cheonan, Korea.
Department of Surgery, Dankook University Hospital, Cheonan, Korea.
Anesth Pain Med (Seoul). 2022 Jan;17(1):75-86. doi: 10.17085/apm.21094. Epub 2022 Jan 19.
Postoperative pain occurring after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is difficult to control because of extensive surgical injuries and long incisions. We assessed whether the addition of a four-quadrant transabdominal plane (4Q-TAP) block could help in analgesic control.
Seventy-two patients scheduled to undergo elective CRS with HIPEC and intravenous patient-controlled analgesia (IV PCA) were enrolled. The patients received 4Q-TAP blocks in a 10 ml mixture of 2% lidocaine and 0.75% ropivacaine per site (4Q-TAP group, n = 36) or normal saline (control group, n = 33). Oxycodone in the post-anesthesia care unit (PACU) and pethidine or tramadol in the ward were used as rescue analgesics. The primary outcome was less than 3 times of rescue analgesic administration (%) in the ward for 5 postoperative days. Secondary endpoints included oxycodone requirement in PACU, fentanyl doses of IV PCA, morphine milligram equivalent (MME) of total opioid use, hospital stay, and postoperative complications.
During 5 postoperative days, there was no difference in pain scores and total rescue analgesic administration between two groups. However, the use of oxycodone in PACU (P = 0.011), fentanyl requirement in IV PCA (P = 0.029), and MME/kg of total opioid use (median, 2.35 vs. 3.21 mg/kg, P = 0.009) were significantly smaller in the 4Q-TAP group. Hospital stay and incidence of postoperative morbidity were similar in both groups.
The 4Q-TAP block enhanced multimodal analgesia and decreased opioid requirements in patients with CRS with HIPEC, but did not change postoperative recovery outcomes.
减瘤手术(CRS)联合热灌注化疗(HIPEC)术后因手术创伤大、切口长,疼痛难以控制。我们评估了增加四象限腹横肌平面(4Q-TAP)阻滞是否有助于镇痛控制。
纳入72例计划行择期CRS联合HIPEC及静脉自控镇痛(IV PCA)的患者。患者每部位接受10 ml由2%利多卡因和0.75%罗哌卡因组成的混合液进行4Q-TAP阻滞(4Q-TAP组,n = 36)或生理盐水(对照组,n = 33)。麻醉后恢复室(PACU)使用羟考酮,病房使用哌替啶或曲马多作为补救镇痛药。主要结局是术后5天内在病房补救镇痛药使用少于3次的患者比例(%)。次要终点包括PACU中羟考酮的需求量、IV PCA中的芬太尼剂量、总阿片类药物使用的吗啡毫克当量(MME)、住院时间和术后并发症。
术后5天内,两组疼痛评分和补救镇痛药总使用量无差异。然而,4Q-TAP组在PACU中羟考酮的使用量(P = 0.011)、IV PCA中芬太尼的需求量(P = 0.029)以及总阿片类药物使用的MME/kg(中位数,2.35 vs. 3.21 mg/kg,P = 0.009)显著更低。两组住院时间和术后发病率相似。
4Q-TAP阻滞增强了CRS联合HIPEC患者的多模式镇痛并降低了阿片类药物需求量,但未改变术后恢复结局。